Clinical trial computer systems
This article was originally published in The Gray Sheet
Executive Summary
FDA final guidance states that in order for the agency to "reconstruct" a study, applicants must make available all versions of application software, operating systems and software development tools associated with the clinical trial process. Issued May 10, the document addresses systems used "to create, modify, maintain, archive, retrieve or transmit clinical data intended for submission to FDA"